Article Text

Download PDFPDF
Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil

Statistics from


  • Source of funding Pfizer.


  • Competing interests HF has been a consultant or speaker or received grant support from several pharmaceutical and biotechnology companies in the past 5 years, including Pfizer, Elan, Forest, Sanofi-aventis, Janssen AI, Lilly, Avid and others.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles